Ainos enters VELDONA license deal with partner-funded development, secures $600,000 upfront fee

• Ainos outlined a VELDONA license deal with a pharmaceutical development partner, shifting clinical and regulatory execution to the licensee.
• Agreement includes an initial license fee of USD 600,000, payable within 15 business days once payment conditions are met.
• Partner funds development for the first two globally licensed indications, Sjögren's disease, thrombocytopenia, reducing Ainos’ internal funding needs.
• Ainos will receive 25% of applicable net sublicensing revenue, creating potential payments before product approval if sublicenses generate consideration.
• Company also cited a potential USD 10 million framework tied to the initial fee, additional indication licenses, first-sublicense fee.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ainos Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609280800ACCESSWRNAPR_____1227489) on September 28, 2026, and is solely responsible for the information contained therein.